paclitaxel/diarrea

El enlace se guarda en el portapapeles.

Elija el tipo de clasificación

Página 1 desde 508 resultados

A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE To inform lumretuzumab and pertuzumab dose modifications in order to decrease the incidence, severity, and duration of the diarrhea events in metastatic breast cancer patients treated with a combination therapy of lumretuzumab (anti-HER3) in combination with pertuzumab (anti-HER2) and

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE Dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel and trastuzumab (PT) is feasible. Lapatinib is effective in the treatment of human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer. We conducted a pilot study of dose-dense AC followed by

Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE The objective of this study was to determine the incidence of grade 3 and 4 gastrointestinal toxicity and the prevalence of Clostridium difficile-associated diarrhea (CDAD) in patients with gynecologic malignancies treated with paclitaxel-based chemotherapy regimens. METHODS We

Paclitaxel-Associated Diarrhea in a 58-Year-Old Woman.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Life-threatening Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE Platinum-based chemotherapy is the recognized first-line treatment for metastatic nasopharyngeal carcinoma (NPC). However, no standard treatment regimens have been established. This phase II study was designed to evaluate the efficacy and safety of a paclitaxel, cisplatin and 5-FU

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE This phase II study evaluated the safety and clinical activity of pazopanib, a potent and mutlitargeted tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs)-1, -2 and -3, platelet-derived growth factor receptor (PDGFR)-α and β, and cKit, in combination

Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

BACKGROUND The combination of paclitaxel (P) and carboplatin (C) is an effective treatment for advanced NSCLC. Gemcitabine (G) is an active new drug. We planned a phase I study to find the maximum tolerated dose (MTD) of the PCG combination. A phase II study was subsequently conducted to evaluate

Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies. METHODS Thirty patients with metastatic or locally advanced (unresectable or recurrent)

Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE The purpose of this study was to determine whether addition of the synthetic rexinoid bexarotene (Targretin; Eisai Inc, Woodcliff Lake, NJ) to standard first-line carboplatin and paclitaxel therapy provides additional survival benefit in patients with advanced non-small-cell lung cancer

Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE A phase II study of weekly paclitaxel combined with S-1, a novel oral fluoropyrimidine, was performed to evaluate the efficacy and tolerability in unresectable or metastatic gastric cancer. METHODS Twenty-nine patients with unresectable and/or metastatic gastric cancer were enrolled in the

Metronomic weekly paclitaxel in advanced unresectable esophageal cancer.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

BACKGROUND Advanced esophageal cancer is aggressive with an expected median survival of 6-7 months. Combination chemotherapy regimens provide effective palliation, but result in substantial toxicity. METHODS Retrospective analysis of prospectively collected data of patients with advanced esophageal

Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE Conventional polyethoxylated castor oil (PCO)-based paclitaxel is associated with major adverse drug reactions (ADRs). Nanoxel, a nanoparticle-based formulation, may improve its tolerability by removing the need for PCO vehicle, and also permit its use in a higher dose. We conducted

Preliminary experience with paclitaxel in advanced bladder cancer.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

In a phase II Eastern Cooperative Oncology Group trial, single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was administered to 26 patients with advanced urothelial cancer who had not received prior systemic chemotherapy. Paclitaxel was given at a dose of 250 mg/m2 by

Nursing implications in the administration of paclitaxel (TAXOL).

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Paclitaxel is an antimicrotubule agent that was recently approved by the Food and Drug Administration (FDA). Because it is insoluble in water, it is mixed with Cremophor EL (polyoxyethylated castor oil). The addition of Cremophor requires the use of glass bottles or polyolefin or polypropylene bags

Únete a nuestra
página de facebook

Herbal & Natural Medicine

La base de datos de hierbas medicinales más completa respaldada por la ciencia

Funciona en 55 idiomas
Curas a base de hierbas respaldadas por la ciencia
Reconocimiento de hierbas por imagen
Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
Leer publicaciones científicas relacionadas con su búsqueda
Buscar hierbas medicinales por sus efectos.
Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.